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8 weeks. This hypothesis is supported by our finding that all
MACEs in the early-surgery group occurred in patients in whom
antiplatelet therapy was discontinued, including 3 events in the 17
patients with bare-metal stents in whom antiplatelet therapy was
discontinued and 2 events in 9 patients with drug-eluting stents
without antiplatelet therapy. In contrast to our findings, Reddy
et al. (5) did not show an association between discontinuation of
antiplatelet therapy and perioperative MACEs in 56 patients with
prior bare-metal stenting. This might have been attributable to the
small number of events in their study.
The small number of events is also a limitation of the current
study. Multivariate analysis could not be performed because of this
small number. However, the difference found between those
patients who continued their antiplatelet therapy and those who
did not deserves attention, and, until more evidence is available,
antiplatelet therapy during surgery should be continued unless
there is an absolute contraindication.
Olaf Schouten, MD
Ron T. van Domburg, PhD
Jeroen J. Bax, MD, PhD
Peter J. de Jaegere, MD, PhD
Martin Dunkelgrun, MD
Harm H. H. Feringa, MD
Sanne E. Hoeks, MSc
*Don Poldermans, MD, PhD
*Erasmus Medical Center
Dr. Molewaterplein 40
3015 GD Rotterdam
the Netherlands
E-mail: d.poldermans@erasmusmc.nl
doi:10.1016/j.jacc.2006.10.004
Please note: Dr. Schouten is supported by an unrestricted research grant from The
Netherlands Organization for Health Research and Development (ZonMw), the
Hague, the Netherlands, and an unrestricted research grant from “Lijf & Leven”
Foundation, Rotterdam, the Netherlands. Dr. Dunkelgrun is supported by an
unrestricted research grant (#2003B143) from the Netherlands Heart Foundation, the
Hague, the Netherlands. Harold L. Dauerman, MD, served as Guest Editor for this
article.
REFERENCES
1. Kaluza GL, Joseph J, Lee JR, Raizner ME, Raizner AE. Catastrophic
outcomes of noncardiac surgery soon after coronary stenting. J Am Coll
Cardiol 2000;35:1288–94.
2. Wilson SH, Fasseas P, Orford JL, et al. Clinical outcome of patients
undergoing non-cardiac surgery in the two months following coronary
stenting. J Am Coll Cardiol 2003;42:234–40.
3. Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and
prospective validation of a simple index for prediction of cardiac risk of
major noncardiac surgery. Circulation 1999;100:1043–9.
4. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction
redefined—a consensus document of The Joint European Society of
Cardiology/American College of Cardiology Committee for the redef-
inition of myocardial infarction. J Am Coll Cardiol 2000;36:959–69.
5. Reddy PR, Vaitkus PT. Risks of noncardiac surgery after coronary
stenting. Am J Cardiol 2005;95:755–7.
Letters to the Editor
Time Dependence
of Defibrillator Benefit
Postcoronary Revascularization
In a recent issue of the Journal,Goldenberg et al. (1), in a subgroup
analysis of MADIT-II (Multicenter Automatic Defibrillator Im-
plantation Trial) (2), showed that in patients with ischemic left
ventricular dysfunction who underwent coronary revascularization
(CR), the efficacy of implantable cardioverter-defibrillator (ICD)
therapy was not apparent when the device was implanted 6 months
or less following CR. The authors concluded a time dependence of
the ICD therapy efficacy and raised the question of the optimal
timing of device implantation following CR. In our opinion, the
issues raised by the study should instead focus on the reasons why
the ICD benefit was only apparent when implanted after long time
frames following revascularization.
In view of the elapsed time following CR by the time of
patient enrollment, we can assume that the distinguishing
feature between patients enrolled early and those enrolled late
after CR resides in the probability of recurrent ischemia. This
was moreover the rationale of the selected time frames based on
the probability of coronary artery disease progression. Because
several observations suggest a role for silent (or overt) ischemia
as at least a contributing factor to sudden death (3,4), the lack
of survival benefit of ICD therapy in the group characterized by
a lower probability of ischemia may therefore be attributed to
the prevention of recurrent ischemia by revascularization. This
hypothesis is further substantiated by the CABG (Coronary
Artery Bypass Graft)-Patch trial (5) where no survival benefit
was conferred by prophylactic ICD in patients undergoing CABG
with depressed left ventricular function.
Accordingly, this subgroup analysis (1) further confirms the
importance of revascularization to lower the risk of sudden cardiac
death. As it is reasonable to first treat the contributing factors
rather than the consequences, a systematic evaluation of the
coronary artery status with CR if required prior to prophylactic
ICD implantation should be the conclusion to draw from this
subset of the MADIT-II study. The investigators raised the
question of the optimal timing of device implantation. However,
considering time frames from up to and more than 5 years
following CR, the “timing” for a significant life-saving benefit of
ICD to become apparent also coincides with an increasing prob-
ability of progression of coronary artery lesions. We may then
assume that a substantial proportion of patients in these time
frames would actually have qualified for a coronary evaluation prior
to ICD implantation.
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The recruitment of patients with remote myocardial infarction
and depressed left ventricular function without systematic coronary
artery status evaluation was precisely one of the limitations raised
by the MADIT-II study (6). Is it then appropriate to implement
the MADIT-II in patients considered for prophylactic ICD after
a coronary evaluation has been performed as warranted in clinical
practice in light of the present observations? Indeed, Goldenberg
et al. (1) observe that those patients who qualify for a revascular-
ization procedure subsequently performed will not enjoy a signif-
icant survival benefit due to the ICD. Similarly, for those whom a
revascularization procedure is not needed, hence without an
ischemic substrate, the corollary of the study suggests that their
risk of sudden death might be lower than expected and hence limit
the detectable benefit of ICD.
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Reply
We agree with the suggestion of Drs. Pascale and Fromer that a
coronary evaluation should be carried out in MADIT (Multicenter
Automatic Defibrillator Implantation Trial)-II–type patients with
a history of remote myocardial infarction (MI) and depressed left
ventricular dysfunction. This is also in agreement with current
guidelines for the management of patients with heart failure, in
which coronary angiography is recommended in patients who
present with angina or significant ischemia (Class I) and to eligible
asymptomatic heart failure patients with suspected coronary dis-
ease (Class IIa) (1). Our data, published in JACC, demonstrate that
coronary revascularization (CR) by either coronary artery bypass
graft surgery (CABG) or coronary angioplasty confers a significant
reduction in the risk of sudden cardiac death (SCD) in this
population (2). Furthermore, in the CABG-Patch trial (3) and in
the current MADIT-II subgroup analysis (2), no implantable
cardioverter-defibrillator (ICD) benefit was observed when the
device was implanted at the time of elective CABG or in the
immediate post-CR period.
Nevertheless, further studies are required to determine to what
extent complete CR provides a long-term protective effect against
SCD. In our analysis, the benefit conferred by CR was shown to
be time-dependent, and was no longer evident six months after the
revascularization procedure. Therefore, we continue to recommend
primary ICD therapy in MADIT-II type patients because it is
associated with a significant survival benefit in post-MI patients
with left ventricular dysfunction (4). Coronary evaluation should
be performed in eligible patients, and may be followed by complete
or partial revascularization. However, our data suggest that defi-
brillator implantation may be deferred for only a limited time-
period after CR in this high-risk population. In addition, Drs.
Pascale’s and Fromer’s suggestion, namely that benefit of the ICD
is limited in patients without an ischemic substrate, is not
supported by findings from recent primary intervention trials (5,6).
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